Nirsevimab decreased the subsequent risk of respiratory syncytial virus infection and wheezing in the 2023-2024 RSV season

Pediatr Res. 2025 Jan 9. doi: 10.1038/s41390-024-03782-4. Online ahead of print.
No abstract available

Publication types

  • Letter